Sino Biological - ProPure™ Endotoxin-Free Proteins
Lonza || Harvest 40 years of primary cell expertise

EDITORIAL SECTION

KNOWLEDGE BANK

  • Articles

    Pharma Display Advertising: Boost Leads & Webinar Registrations Instantly

    With the ever growing competition in the pharmaceutical industry firms are always trying to find viable methods of accessing decisionmakers creating qualified leads and marketing thought leadership opportunities eg webinars The old ways of outreach are no longer effective in the digitalfirst environment where the executives of healthcare the researchers of pharmaceuticals and the leaders of the in...

TOP ARTICLES

press releasesRead more...

The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard

When we discuss bacterial infections we often think of exotoxinsthose soluble proteins actively secreted by bacteriawhile overlooking endotoxins which are more insidious but equally dangerous Endotoxins are not released by bacteria rather they are natural components residing in the bacterial

Ramarketing acquires US market research firm ISR

Strategic life sciences marketing agency ramarketing has completed the acquisition of ISR Market Research a specialist agency based in North Carolinas Research Triangle Park RTP one of the largest pharmaceutical and biopharma hubs in North America

Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)

Affinia Therapeutics Affinia an innovative gene therapy company with a pipeline of firstinclass andor bestinclass adenoassociated virus AAV gene therapies initially for devastating cardiovascular diseases

Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients

Vasomune Therapeutics Inc a clinicalstage biopharmaceutical company today announced US Food and Drug Administration FDA clearance of the Investigational New Drug IND application to develop Pegevongitide AV

09 - 11

Mar 2026

8th International Conference

8105, Suite 112, Rasor Blvd, Plano TX 75024, USA

10 - 12

Mar 2026

Bioprocessing Summit Europe 2026

InterContinental Barcelona, Spain

10 - 10

Mar 2026

Age of AI Europe 2026

Institute of Engineering and Technology (IET) London,UK

10 - 12

Mar 2026

11 - 12

Mar 2026

16 - 17

Mar 2026

Pharma USA 2026

Philadelphia, PA , USA

16 - 18

Mar 2026

Pharmaceutics and Novel Drug

Kuala Lumpur, Malaysia

16 - 18

Mar 2026

Advanced Clinical Research

Kuala Lumpur, Malaysia

LATEST NEWSRead more...

CSL to expand plasma therapy manufacturing plant in Illinois

CSL Limited has begun expansion work at its plasma therapy manufacturing plant in Kankakee Illinois as part of the companys global manufacturing growth strategy and efforts to strengthen production in the United States

FDA Eases Biosimilar Development Requirements

The US FDA is reducing study requirements for biosimilars to enhance market competition and cut development costs by an estimated million per drug

FDA Greenlights Boehringer's HERNEXEOS as First Targeted Therapy for HER2-Mutant NSCLC

The US FDA has approved Boehringer Ingelheims HERNEXEOS zongertinib tablets as the first targeted initial therapy for adults with advanced nonsmall cell lung cancer harboring HER ERBB tyrosine kinase domain activating mutations

INOVIO and Akeso Collaborate to Study New Combination Therapy for Glioblastoma

INOVIO and Akeso Inc have entered into a clinical trial collaboration and supply agreement to evaluate a new combination therapy for the treatment of Glioblastoma GBM an aggressive form of brain cancer

Sinopia Biosciences to Collaborate with Ono Pharmaceutical on Target Discovery for Rare Metabolic Disorders

Sinopia Biosciences Inc has announced a target discovery collaboration with Ono Pharmaceutical Co Ltd focused on a group of rare metabolic disorders The disorders remain undisclosed and are associated with significant unmet medical need

Vanda Receives FDA Grant for Formal Hearing on HETLIOZ® Application

Vanda Pharmaceuticals Inc has announced that the US Food and Drug Administration FDA has granted its request for a formal evidentiary public hearing regarding the proposed refusal to approve its supplemental